Nektar Therapeutics Files 8-K
Ticker: NKTR · Form: 8-K · Filed: Feb 4, 2025 · CIK: 906709
Sentiment: neutral
Topics: sec-filing, 8-k, financial-reporting
TL;DR
Nektar filed an 8-K, standard SEC update, no major news.
AI Summary
Nektar Therapeutics filed an 8-K on February 4, 2025, reporting other events and financial statements. The filing does not contain specific details on new material events or financial figures beyond standard reporting requirements.
Why It Matters
This 8-K filing indicates Nektar Therapeutics is providing updates and financial information to the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for 'Other Events' and financial statements, not indicating any immediate material changes or risks.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- February 4, 2025 (date) — Date of earliest event reported
- 455 Mission Bay Boulevard South (address) — Principal Executive Offices
- San Francisco, California 94158 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Nektar Therapeutics?
The primary purpose of this 8-K filing is to report 'Other Events' and to include financial statements and exhibits as of February 4, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is February 4, 2025.
What is Nektar Therapeutics' principal executive office address?
Nektar Therapeutics' principal executive office is located at 455 Mission Bay Boulevard South, San Francisco, California 94158.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Nektar Therapeutics' IRS Employer Identification Number?
Nektar Therapeutics' IRS Employer Identification Number is 94-3134940.
Filing Stats: 754 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2025-02-04 16:15:22
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
Filing Documents
- ea0229922-8k_nektar.htm (8-K) — 26KB
- 0001213900-25-010085.txt ( ) — 194KB
- nktr-20250204.xsd (EX-101.SCH) — 3KB
- nktr-20250204_lab.xml (EX-101.LAB) — 33KB
- nktr-20250204_pre.xml (EX-101.PRE) — 22KB
- ea0229922-8k_nektar_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On February 4, 2025, Mary Tagliaferri MD resigned from her position as Senior Vice President and Chief Medical Officer of Nektar Therapeutics, a Delaware corporation (the "Company"), effective immediately. Dr. Tagliaferri resigned for personal reasons, and her resignation is not the result of any disagreement with the Company on any matter relating to its strategies or operations and does not arise from any concern with the conduct or integrity of any of the Company's clinical trials. Brian Kotzin, MD, who was serving as the Company's strategic advisor to the rezpegaldesleukin program since April 2023, has assumed the responsibilities of interim Chief Medical Officer. From 2017 to 2023, Dr. Kotzin supported the clinical development of rezpegaldesleukin in several different capacities at the Company. Dr. Kotzin has over 40 years of expertise in immunology and has extensive development and management experience. From 2004 to 2015, Dr. Kotzin was at Amgen, where he served as Vice President, Global and Clinical Development and Head, Inflammation Therapeutic Area, directing the global development efforts for Amgen product candidates in the inflammation area. During his time at Amgen, he also served as Vice President of Medical Sciences, which encompassed early development, biomarker development, and clinical immunology. Prior to entering the life sciences industry, Dr. Kotzin held several positions in academia, including a professor at the University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of disease. He has also held leadership roles at several national organizations, including as a member of the American College of Rheumatology (ACR) Board of Directors and is currently an elected Master of the ACR, Member and Chairperson of the NIH Immunological Sciences Study Section, Chairperson of the NIH Autoimmunity Centers of Excellence, and Member of the Board of Directors for the Federation of Clinical
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: February 4, 2025 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2